Japanese researchers have announced on Friday the pluripotentiary cells (iPS) transplanted in the brain of a patient with Parkinson's disease in the world.
Kyoto University team has introduced 2.4 million iPS cells –can make any type of cell– three hours of operation in October at the left side of the brain.
50 years old man, She has shown good health care and is in control of her for two years, Kyoto University made a statement.
If the problem persists in the next six months, researchers implant 2.4 million additional cells, this time on the right of the brain.
These donated iPS cells convert neurotransmitters that engage in motor management, and produce dopamine.
In July, Kyoto University announced that it would conduct a clinical trial with seven people aged 50 to 69.
It is characterized by Parkinson's disease neuronal degradation, such as tremors, muscular stiffness, and loss of body movement, gradually increasing symptoms.
According to the American Parkinson's Disease Foundation, it affects more than ten million people in the world. The currently available therapy "improves symptoms without slowing the development of the disease," explains the fund.
New research is aimed at rebuilding evil.
Before clinical trials in humans, the experiment was carried out in apes with human stem cells, which, according to research published in the August issue of Nature in August 2017, helped improve priming behavior of Parkinson's types. .
The survival rate of transplanted cells was closely monitored by injection in the primate brain for two years, and no tumor was detected.
Induction-coated pluripotentiary cells (iPS) are adult cells, almost embryonic to generate four genes (usually adults inactive). This genetic manipulation allows the production of any cell in accordance with the location of the transplanted body.
The use of IPS cells does not cause significant ethical problems than stem cells from human embryos.